CANNABIDIOL Chemische Eigenschaften,Einsatz,Produktion Methoden
R-S?tze Betriebsanweisung:
R11:Leichtentzündlich.
R23/24/25:Giftig beim Einatmen, Verschlucken und Berührung mit der Haut.
R39/23/24/25:Giftig: ernste Gefahr irreversiblen Schadens durch Einatmen, Berührung mit der Haut und durch Verschlucken.
S-S?tze Betriebsanweisung:
S36/37:Bei der Arbeit geeignete Schutzhandschuhe und Schutzkleidung tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn m?glich, dieses Etikett vorzeigen).
S16:Von Zündquellen fernhalten - Nicht rauchen.
S7:Beh?lter dicht geschlossen halten.
Chemische Eigenschaften
Off-White Solid
Verwenden
Major non-psychoactive constituent of Cannabis. Exhibits multiple bioactivities including anticonvulsant, anxiolytic and anti-inflammatory effects. The (+)-isomers were more active than the (-)-isomers.
Definition
ChEBI: An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.
Biologische Aktivit?t
Non-psychotropic constituent of cannabis that is anticonvulsive, antihyperalgesic and neuroprotective in vivo . GPR55 and weak CB 1 antagonist (IC 50 values are 0.445 and 3.35 μ M), CB 2 receptor inverse agonist and inhibitor of anandamide uptake (IC 50 = 27.5 μ M). Also a weak agonist at VR1 vanilloid receptors (EC 50 = 3.5 μ M).
Pharmakologie
Cannabidiol, a constituent of the cannabis plant, has been receiving considerable attention of late for its potential therapeutic utility, including potential anxiolytic, anticonvulsant,anti-inflammatory, and neuroprotective effects. Cannabidiol has a complex pharmacology. In contrast to THC, cannabidiol has minimal affinity for CB1 and CB2 receptors and produces no intoxication. The effects of cannabidiol in combination with THC have been mixed, with some data suggesting it may reduce THC’s mood-altering and cognitive effects, while others show no effect. If oral cannabidiol reduces cannabis intoxication, it could be a potential medication to treat CUD. However, Haney et al. tested a range of cannabidiol doses (200–800 mg) in combination with active and placebo cannabis and found no cannabidiol effect on the subjective, reinforcing, or cardiovascular effects of smoked cannabis, providing little support for cannabidiol’s utility as a medication to reduce cannabis’ positive reinforcing and subjective effects.
CANNABIDIOL Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
